Zoetis Inc. discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides medicated feed additives that offer medicines to livestock; and other pharmaceutical products, which comprise allergy and dermatology, pain and sedation, antiemetic, reproductive, and oncology products. In addition, the company offers other product categories, including nutritionals and agribusiness services, as well as products and services in complementary areas, such as biodevices, diagnostics, and genetics. It markets its products to veterinarians, livestock producers, and people who raise and care for farm and companion animals through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:ZTS
CUSIP98978V10
Phone973-822-7000
Debt
Debt-to-Equity Ratio2.51
Current Ratio4.27
Quick Ratio2.83
Price-To-Earnings
Trailing P/E Ratio35.54
Forward P/E Ratio27.96
P/E Growth1.89
Sales & Book Value
Annual Sales$5.31 billion
Price / Sales7.78
Cash Flow$2.9239 per share
Price / Cash29.17
Book Value$3.67 per share
Price / Book23.24
Profitability
EPS (Most Recent Fiscal Year)$2.40
Net Income$864 million
Net Margins17.97%
Return on Equity68.51%
Return on Assets15.00%
Miscellaneous
Employees9,200
Outstanding Shares483,860,000
Market Cap$41,331.79
Zoetis (NYSE:ZTS) Frequently Asked Questions
What is Zoetis' stock symbol?
Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."
How often does Zoetis pay dividends? What is the dividend yield for Zoetis?
Zoetis declared a quarterly dividend on Tuesday, May 15th. Shareholders of record on Friday, July 20th will be given a dividend of $0.126 per share on Tuesday, September 4th. This represents a $0.50 annualized dividend and a yield of 0.59%. The ex-dividend date of this dividend is Thursday, July 19th. View Zoetis' Dividend History.
How were Zoetis' earnings last quarter?
Zoetis Inc (NYSE:ZTS) released its quarterly earnings results on Wednesday, May, 2nd. The company reported $0.75 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.69 by $0.06. The business had revenue of $1.37 billion for the quarter, compared to analysts' expectations of $1.35 billion. Zoetis had a return on equity of 68.51% and a net margin of 17.97%. The firm's revenue was up 11.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.53 earnings per share. View Zoetis' Earnings History.
When is Zoetis' next earnings date?
What guidance has Zoetis issued on next quarter's earnings?
Zoetis updated its FY18 earnings guidance on Wednesday, May, 2nd. The company provided EPS guidance of $2.96-3.10 for the period, compared to the Thomson Reuters consensus estimate of $3.04. The company issued revenue guidance of $5.675-5.800 billion, compared to the consensus revenue estimate of $5.74 billion.
What price target have analysts set for ZTS?
16 analysts have issued 1-year target prices for Zoetis' shares. Their predictions range from $62.00 to $98.00. On average, they anticipate Zoetis' stock price to reach $84.8571 in the next twelve months. This suggests that the stock has a possible downside of 0.5%. View Analyst Ratings for Zoetis.
What is the consensus analysts' recommendation for Zoetis?
16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 7 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Zoetis stock?
Here are some recent quotes from research analysts about Zoetis stock:
- 1. Cantor Fitzgerald analysts commented, "We rate ZTS as 12-month price target of $98. Given the company’s durable business model and the positive outlook for macro factors, we think the multiple will hold and upwards earnings revisions should drive shares higher. Valuation Summary We use a blend of DCF and multiples analysis (EV/EBITDA) to get to our 12- month price target of $98." (5/16/2018)
- 2. According to Zacks Investment Research, "Zoetis faces stiff competition from other animal health medicines and vaccines companies like Merck Animal Health (the animal health division of Merck), Elanco (the animal health division of Eli Lilly), Bayer Animal Health (the animal health division of Bayer) and Boehringer Ingelheim Animal Health (the animal health division of Boehringer Ingelheim). Disease outbreak among animals is a material cause of concern for Zoetis’ livestock products.In addition, companion animal health products are often directly prescribed and dispensed by veterinarians. The swine business is being impacted by competition for Fostera. These competitive pressures could adversely affect the company’s business and operating results. However, shares of the company have outperformed the industry in the last six months." (1/13/2018)
Who are some of Zoetis' key competitors?
Some companies that are related to Zoetis include AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN), Shire (SHPG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN) and Takeda Pharmaceutical (TKPYY).
Who are Zoetis' key executives?
Zoetis' management team includes the folowing people:
- Mr. Juan Ramón Alaix, CEO & Director (Age 67)
- Mr. Glenn C. David, Exec. VP & CFO (Age 46)
- Dr. Catherine A. Knupp, Exec. VP and Pres of R&D (Age 57)
- Mr. Clinton A. Lewis Jr., EVP and Pres of International Ops., Commercial Devel., Global Genetics & Aquatic Health (Age 51)
- Ms. Kristin C. Peck, Exec. VP and Group Pres of U.S. Operations, Bus. Devel. & Strategy (Age 47)
Has Zoetis been receiving favorable news coverage?
Media coverage about ZTS stock has trended positive this week, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Zoetis earned a daily sentiment score of 0.39 on Accern's scale. They also gave media stories about the company an impact score of 49.35 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
Who are Zoetis' major shareholders?
Zoetis' stock is owned by many different of retail and institutional investors. Top institutional investors include Bank of Montreal Can (0.27%), Atalanta Sosnoff Capital LLC (0.09%), DAVENPORT & Co LLC (0.08%), Boston Advisors LLC (0.08%), Chicago Capital LLC (0.06%) and Gofen & Glossberg LLC IL (0.06%). Company insiders that own Zoetis stock include Andrew Fenton, Catherine A Knupp, Heidi C Chen, Khosla Sanjay, Kristin C Peck, Michael B Mccallister, Roman Trawicki and Roxanne Lagano. View Institutional Ownership Trends for Zoetis.
Which institutional investors are selling Zoetis stock?
ZTS stock was sold by a variety of institutional investors in the last quarter, including Westpac Banking Corp, Rockland Trust Co., Boston Advisors LLC, DAVENPORT & Co LLC, Fred Alger Management Inc., Hartford Investment Management Co., Jag Capital Management LLC and Meag Munich Ergo Kapitalanlagegesellschaft MBH. Company insiders that have sold Zoetis company stock in the last year include Heidi C Chen, Khosla Sanjay, Kristin C Peck, Roman Trawicki and Roxanne Lagano. View Insider Buying and Selling for Zoetis.
Which institutional investors are buying Zoetis stock?
ZTS stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Cornerstone Wealth Management LLC, Chicago Capital LLC, Cobiz Wealth LLC, Daiwa SB Investments Ltd., State of Alaska Department of Revenue, Pendal Group Ltd and Copper Rock Capital Partners LLC. View Insider Buying and Selling for Zoetis.
How do I buy shares of Zoetis?
Shares of ZTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zoetis' stock price today?
One share of ZTS stock can currently be purchased for approximately $85.29.
How big of a company is Zoetis?
Zoetis has a market capitalization of $41.33 billion and generates $5.31 billion in revenue each year. The company earns $864 million in net income (profit) each year or $2.40 on an earnings per share basis. Zoetis employs 9,200 workers across the globe.
How can I contact Zoetis?
Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company can be reached via phone at 973-822-7000 or via email at [email protected]
MarketBeat Community Rating for Zoetis (NYSE ZTS)
MarketBeat's community ratings are surveys of what our community members think about Zoetis and other stocks. Vote "Outperform" if you believe ZTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZTS will underperform the S&P 500 over the long term. You may vote once every thirty days.
